U.S. FDA approves AstraZeneca's bladder cancer drug

(Reuters) - The U.S. Food and Drug Administration on Monday granted accelerated approval to AstraZeneca Plc's immuno-oncology drug to treat a type of bladder cancer in patients whose disease progressed following chemotherapy.